To investigate IL-6 as a potential drug target in the treatment of depression, the Insight study seeks to assess the role of IL-6 in depression pathogenesis and the mechanisms by which it may affect mood and cognition by utilizing the IL-6 inhibitor, tocilizumab, in depressive patients with and without low-grade inflammation [176]. The gene discussed is IL6; the disease is depressive symptom measurement.